ITF Therapeutics LLC

Our team was proud to join the Duchenne muscular dystrophy (DMD) community at Parent Project Muscular Dystrophy’s 30th Annual Conference! From our participation in the Patient Assistance Program sessions to our chats around the exhibit floor, we had the chance to hear from so many individuals living with DMD and their families about their personal experiences and hopes for the future. It was inspiring to see the community join together to show support, celebrate each other’s achievements, and learn about the latest advances in research. During the meeting, we also had the opportunity to participate in PPMD’s Duchenne Drug Development Roundtable and lead a focus group that provided invaluable insights on the needs and goals of the DMD community. In addition, our VP, Medical Affairs Scott Baver, Ph.D., delivered a special presentation to share information about our work to advance a therapeutic option for DMD and discuss the services that we have developed to support individuals living with DMD and their families. We are grateful to PPMD for hosting this important event and are honored to serve this resilient community. #Duchenne #DMD #RareDiseases

As we join with the Duchenne muscular dystrophy (DMD) community at the Parent Project Muscular Dystrophy’s 30th Annual Conference, our VP, Medical Affairs Scott Baver, Ph.D., will be delivering a presentation to share information about a therapeutic option for DMD and provide an overview of the resources and services that we have developed to support individuals living with DMD and their families. Check out the conference agenda for more details: https://lnkd.in/eJqUzYEf We are privileged to contribute to this event and look forward to engaging in meaningful discussions with members of the DMD community to help discover new opportunities to work together and make a positive impact. #Duchenne #DMD #RareDiseases

The Parent Project Muscular Dystrophy’s 30th Annual Conference not only facilitates education, connection, and inspiration within the Duchenne muscular dystrophy (DMD) community, but also provides an important platform to celebrate the strength of individuals living with DMD and their families. We are deeply honored to serve this resilient community and are excited to participate in this year’s event to actively learn from and engage with attendees who share our commitment to making a positive difference for people living with DMD. During the conference, our team will be available during the Patient Assistance Program 1:1 sessions being held Saturday, June 29 at 9:30 a.m. and 12 p.m. ET to share key updates on the resources and services that we have developed to support people living with DMD and their families. You can also find us at our booth on the exhibit floor – we hope to see you there! https://lnkd.in/exuJZnwq #Duchenne #DMD #RareDiseases

We have had the privilege to listen and learn from many outstanding members of the DMD community whose personal perspectives continue to shape and empower our work. Guided by the valued feedback that we have received from individuals living with DMD and their families, our team has been focused on developing a complete range of services designed to help meet their diverse needs and deliver new educational resources. We are excited to share that we will be participating in a special webinar with CureDuchenne on Wednesday, June 26 at 2-3 p.m. ET to provide updates on our support program and answer questions from the community. This virtual event is free to attend and open to the public – to join us, register here: https://lnkd.in/giQu5Whi #CureDuchenne #Duchenne #DMD #RareDiseases

Thank you to CureDuchenne for hosting an incredible FUTURES National Conference! Our team was excited to connect with advocates, families, researchers and clinicians for meaningful discussions, to listen and learn about how we can help to support the DMD community. Throughout the conference, we were inspired by the many stories shared by attendees that exemplified the resilience and strength of the global DMD community. As part of the Meeting of the Minds at #2024FUTURES, Samantha Parker, Patient Advocacy and Communication Lead Rare Diseases Europe, ITALFARMACO S.P.A., had the opportunity to participate in an engaging session focused on exploring the rapidly changing research landscape of DMD. In addition, our VP, Medical Affairs Scott Baver, PhD, presented updates on our efforts to advance a therapeutic option for people living with DMD. Thank you to #CureDuchenne and the #DMD community for helping us to further understand how we can work together. We look forward to continuing to collaborate as we implement the important insights shared during FUTURES in our work!

During the CureDuchenne FUTURES National Conference, our VP, Medical Affairs Scott Baver, PhD, will present the latest updates on our efforts to advance a therapeutic option for people living with Duchenne muscular dystrophy (DMD). Join us on Friday, May 24 at 1:30-2:15 p.m. ET. Check out the #2024FUTURES agenda for more details: https://lnkd.in/gV_6Q5er   #CureDuchenne #Duchenne #DMD #RareDiseases

We are proud to support the CureDuchenne FUTURES National Conference being held in Orlando, FL this week. Featuring an engaging program focused on bringing education, connection and hope to the entire Duchenne community, FUTURES promises to be a transformative event for families, researchers, clinicians and advocates dedicated to expanding support for people living with DMD. If you are attending in person, we hope to see you there. You can find us at booth 15 – come stop by! https://lnkd.in/eDajwBMP   #CureDuchenne #2024FUTURES #Duchenne #DMD #RareDiseases

We are partnering with IQVIA to recruit two Regional Sales Directors (West and Southeast – U.S.) to help lead the U.S. launch of an FDA-approved therapy for the treatment of #Duchenne muscular dystrophy (#DMD). If you have 2 years of sales team management and product launch experience in the #RareDisease or neuromuscular/DMD space, learn more and apply today by visiting the links below: 🔹Southeast: https://lnkd.in/eGkBGT3G 🔹West: https://lnkd.in/e4P8SD8t

We are pleased to announce the appointment of Scott Baver, Ph.D., as VP, Medical Affairs at ITF Therapeutics. With extensive experience in medical affairs and research, Scott’s expertise will play a pivotal role in shaping our medical strategy as we advance our work to bring new therapies to people living with rare diseases, including Duchenne muscular dystrophy (DMD). Prior to joining ITF Therapeutics, Scott has held several senior roles at leading life sciences companies where he drove the development of high-impact medical affairs and communications initiatives, supported strategic planning related to clinical development and commercialization, and collaborated with cross functional teams dedicated to pioneering innovative therapeutic solutions for individuals and families with unmet medical needs. Throughout his career, Scott has especially focused on building medical affairs strategies to support programs targeting rare diseases in a broad range of therapeutic areas including neurology, nephrology, and hematology. Welcome to the team, Scott!   #Duchenne #DMD #RareDiseases #Italfarmaco

This week, Italfarmaco is delighted to attend the 8th International Myology Congress in Paris. This congress is a world reference in neuromuscular science and is expected to gather around 900 healthcare professionals, myology scientists and other experts from all over the world. Italfarmaco will present 3 scientific communications and organise the Symposium “New Insights and Clinical Outcomes in Duchenne muscular dystrophy (DMD)”, co-chaired by Prof Isabelle Desguerre (France) and Prof Francesco Muntoni (United Kingdom). At the Symposium, Prof Annemieke Aartsma-Rus (Netherlands) will provide an overview on DMD pathophysiology and Prof Eugenio Mercuri (Italy) will outline the importance of assessments of DMD disease progression in clinical trials and in the clinical practice. As a pharmaceutical leader in research, development, production and commercialisation, Italfarmaco is fully committed to partner with the DMD community across the Globe to bring innovative solutions to address the unmet medical need in this disease. #Myology2024 #Duchenne #DMD #Italfarmaco #Rarediseases